Novo Nordisk’s Alzheimer’s Trials Show No Benefit, Prompting Reassessment of GLP-1 Potential in Brain Health
Novo Nordisk’s early-stage Alzheimer’s studies using an oral form of semaglutide did not slow cognitive decline, renewing questions about whether
Read More